OncoOne
OncoOne is a biotechnology company dedicated to developing precision medicines for inflammation and cancer, aiming to improve patient outcomes and quality of life through innovative targeted therapies. The company focuses on harnessing the high tumor-specificity of oxMIF for systemic treatment of various cancers and inflammatory diseases, utilizing proprietary platforms like Anti-oxMIF and PreTarg-it®. With a team of experienced professionals and collaborations with top academic and industry partners, OncoOne is advancing its pipeline in oncology and chronic inflammatory diseases, aiming to reshape standards of patient care.
Industries
Nr. of Employees
small (1-50)
OncoOne
Höhenstraße 19/2, 3400 Klosterneuburg, Austria
Products
Therapeutic antibody programs targeting disease-associated oxidized protein isoforms
Development of monoclonal antibody therapeutics that selectively bind an oxidized isoform of a protein found at inflammation and tumor sites, intended for systemic treatment of solid tumors and chronic inflammatory diseases.
Pre-targeted radiotherapy platform using bispecific antibodies
A modular platform that uses bispecific antibodies to pretarget radionuclides to tumor tissue, separating targeting and payload delivery to increase selectivity of radioimmunotherapy.
Therapeutic antibody programs targeting disease-associated oxidized protein isoforms
Development of monoclonal antibody therapeutics that selectively bind an oxidized isoform of a protein found at inflammation and tumor sites, intended for systemic treatment of solid tumors and chronic inflammatory diseases.
Pre-targeted radiotherapy platform using bispecific antibodies
A modular platform that uses bispecific antibodies to pretarget radionuclides to tumor tissue, separating targeting and payload delivery to increase selectivity of radioimmunotherapy.
Services
Engagement with pharmaceutical and corporate partners for licensing, strategic alliances and build-to-buy transactions to accelerate clinical development.
Joint R&D projects with academic investigators and CROs covering biophysical characterization, in vivo efficacy testing and translational biomarker development.
Coordination with global CDMOs for cell line development, process and analytical development, and clinical/commercial GMP manufacturing of biologics.
Commissioning GLP-compliant toxicology and pharmacokinetic studies through specialized CRO partners to support IND/clinical entry.
Engagement with pharmaceutical and corporate partners for licensing, strategic alliances and build-to-buy transactions to accelerate clinical development.
Joint R&D projects with academic investigators and CROs covering biophysical characterization, in vivo efficacy testing and translational biomarker development.
Coordination with global CDMOs for cell line development, process and analytical development, and clinical/commercial GMP manufacturing of biologics.
Commissioning GLP-compliant toxicology and pharmacokinetic studies through specialized CRO partners to support IND/clinical entry.
Expertise Areas
- Antibody therapeutic development
- Preclinical translational research
- Biologics CMC and manufacturing
- Targeted oncology and inflammatory disease therapeutics
Key Technologies
- Monoclonal antibody engineering
- Bispecific antibody design
- Pre-targeted radioimmunotherapy
- In silico antibody optimization